Overview: CD30 Immunohistochemistry TestIntroduction: The CD30 Immunohistochemistry Test detects CD30 protein to diagnose Hodgkin lymphoma or anaplastic large cell lymphoma, causing swelling or fever. Aligned with 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected Hodgkin or anaplastic lymphomas.
Other Names: CD30 IHC Assay, Hodgkin Lymphoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD30 testing began in the 1980s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD30 to diagnose Hodgkin lymphoma or anaplastic lymphoma, guides treatment, and evaluates patients with swelling or fever.
Test Parameters: 1. CD30 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fever, or night sweats.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fever, night sweats, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect CD30 in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for Hodgkin lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD30 staining confirms Hodgkin lymphoma or anaplastic large cell lymphoma, guiding chemotherapy or immunotherapy. Negative staining may require further marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD15 IHC, ALK IHC, or PET-CT to confirm Hodgkin or anaplastic lymphoma diagnosis.
Test Limitations: Not specific to one lymphoma type; other conditions may express CD30. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
